Stock Track | AIM VACCINE Soars 6.5% After RSV Vaccine Candidate Gains Clinical Trial Approval in China

Stock Track

Oct 30, 2024

Shares of AIM VACCINE Co Ltd (06660.HK) surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus (RSV) vaccine candidate has obtained approval from China's National Medical Products Administration (NMPA) to proceed to clinical trials.

RSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportunity for AIM VACCINE.

The positive regulatory development for AIM VACCINE's RSV vaccine program appears to be the primary driver behind the strong stock price rally today. Investors are betting that this product candidate has a higher probability of eventual market approval and sales following the green light to initiate human clinical studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1134164116"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134164116\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134164116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134164116","market":"hk","top_or_hot":-1,"title":"Stock Track | AIM VACCINE Soars 6.5% After RSV Vaccine Candidate Gains Clinical Trial Approval in China","media":"Stock Track","content":"<p>Shares of AIM VACCINE Co Ltd (06660.HK) surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus (RSV) vaccine candidate has obtained approval from China's National Medical Products Administration (NMPA) to proceed to clinical trials.</p>\n\n<p>RSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportunity for AIM VACCINE.</p>\n\n<p>The positive regulatory development for AIM VACCINE's RSV vaccine program appears to be the primary driver behind the strong stock price rally today. Investors are betting that this product candidate has a higher probability of eventual market approval and sales following the green light to initiate human clinical studies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AIM VACCINE Soars 6.5% After RSV Vaccine Candidate Gains Clinical Trial Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AIM VACCINE Soars 6.5% After RSV Vaccine Candidate Gains Clinical Trial Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of AIM VACCINE Co Ltd (06660.HK) surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus (RSV) vaccine candidate has obtained approval from China's National Medical Products Administration (NMPA) to proceed to clinical trials.</p>\n\n<p>RSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportunity for AIM VACCINE.</p>\n\n<p>The positive regulatory development for AIM VACCINE's RSV vaccine program appears to be the primary driver behind the strong stock price rally today. Investors are betting that this product candidate has a higher probability of eventual market approval and sales following the green light to initiate human clinical studies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06660","symbol_name":"艾美疫苗","start_time":0,"source_url":"","article_id":"1134164116","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134164116","pubTimestamp":1730251861,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of AIM VACCINE Co Ltd  surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus  vaccine candidate has obtained approval from China's National Medical Products Administration  to proceed to clinical trials.RSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportuni","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06660":"艾美疫苗"},"translate_title":"股票赛道RSV候选疫苗在中国获得临床试验批准后AIM疫苗飙升6.5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06660":1},"content_text":"Shares of AIM VACCINE Co Ltd (06660.HK) surged as much as 6.55% on Tuesday morning after the biopharmaceutical company announced that its mRNA respiratory syncytial virus (RSV) vaccine candidate has obtained approval from China's National Medical Products Administration (NMPA) to proceed to clinical trials.\nRSV is a major cause of respiratory illness in infants and the elderly. Successful development of an effective vaccine against this virus would represent a significant medical breakthrough and commercial opportunity for AIM VACCINE.\nThe positive regulatory development for AIM VACCINE's RSV vaccine program appears to be the primary driver behind the strong stock price rally today. Investors are betting that this product candidate has a higher probability of eventual market approval and sales following the green light to initiate human clinical studies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}